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Abstract
Chondromyxoid fibroma (CMF) is a rare, benign neoplasm of the chondroid, myxoid, and
fibrous tissue. It characteristically affects the lower extremity long bones, although it may rarely
arise within the craniofacial skeleton. We report the diagnosis and management of a 31-year-
old male with a large, incidentally discovered CMF originating from the sphenoid sinus. A
subsequent review of the literature reveals the need to differentiate from more aggressive
neoplasms, such as chondrosarcoma and chondroma, which share radiographic features. A
histopathologic examination is crucial for proper diagnosis and treatment. We discuss clinical
sequelae, highlight the importance of a thorough pre-operative evaluation, and summarize
previously suggested treatment paradigms.
Categories: Otolaryngology
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Introduction And Background
Originally described in 1948 by Jaffe and Lichtenstein, the chondromyxoid fibroma (CMF) is a
neoplasm of cartilaginous origin [1] accounting for <0.5% of all bone tumors [2-4], with a slight
male predominance [5]. Although more commonly found in the metaphysis of long bones,
between 1-5% of CMF cases are reported to occur in the head and neck [5-6].
Cases have been reported in all the paranasal sinuses. Given its benign nature, patients may not
present until secondary symptoms manifest. These symptoms depend on tumor size and
location but may include diplopia, facial pain, exophthalmos, neuralgia, dysarthria, epistaxis,
nasal congestion, headache, bony swelling, or persistent chronic rhinosinusitis [7]. Given the
rarity of CMF, it is crucial to consider more aggressive neoplasms, including chondrosarcoma
and chordoma. We report the diagnosis and management of a patient with CMF originating
from the sphenoid sinus and review the available literature describing its presence within the
head and neck with a focus on the paranasal sinuses.
Case presentation
A previously healthy 31-year-old male presented to the Otolaryngology - Head & Neck Surgery
clinic, with right-sided nasal airway obstruction. Physical examination, including nasal
endoscopy, revealed a large mass within the right nasal passage. He had no associated
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symptoms such as visual complaints, paresthesia, and facial pain. A biopsy was performed in
the operating room, with the histopathologic evaluation revealing a lobular growth pattern with
stellate or spindle-shaped cells in a chondroid background (Figure 1). Well-developed hyaline
cartilage was not present. The pathology report stated the morphological features were
consistent with CMF.
FIGURE 1: Histopathologic images. A (Left). Microscopic
examination reveals stellate or spindle-shaped cells with
abundant chondromyxoid matrix (100x). B (Right) Lesional
cells with eosinophilic cytoplasm and mildly pleomorphic
nuclei containing finely dispersed or homogeneous dark
chromatin (400x).
Prior to definitive resection, preoperative computed tomography (CT) and magnetic resonance
imaging (MRI) imaging were completed for anatomic mapping and surgical planning. CT
revealed a homogeneously enhancing mass with scattered coarse central calcifications. There
was extensive bony remodeling and displacement without aggressive osseous erosion.
Although centered within the right nasal cavity, the lesion was found to erode through the
nasal septum into the left nasal cavity (Figure 2A). The mass extended to the level of the right
nasolacrimal canal anteriorly and to the level of the right choana and nasopharynx inferiorly.
Laterally, the mass deformed the medial wall of the left maxillary sinus and obstructed the
maxillary sinus ostium with associated sinus opacification. Posterior involvement was noted
within the right sphenoid sinus and left posterior ethmoid sinuses. There was no obvious
intracranial or intraorbital extension. MRI with and without contrast supported the CT findings
and demonstrated cystic components (Figure 2B) with relative T2 hypointensity concerning for
high cellularity or a high nuclear-to-cytoplasmic ratio. No perineural spread or adenopathy was
noted.
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FIGURE 2: CT and MR imaging. (A) Contrast-enhanced CT scan
demonstrating an expansile mass centered within the right
nasal cavity with extension into the left nasal passage (white
arrow), with scattered calcifications. (B) The same mass (white
arrow) observed on contrast-enhanced T1-weighted MRI with
heterogeneous uptake.
One month later, the patient underwent endoscopic resection under general anesthesia.
Intraoperatively, the tumor was noted to attach to the planum sphenoidale without dural
involvement. The tumor was found to extend from the sphenoid with erosion through the
posterior septum to involve the left posterior ethmoid cavity (Figure 3).
FIGURE 3: Intraoperative photos. (A) Endoscopic view
demonstrating a mass (black arrow) within the right nasal
cavity at the level of the middle meatus. (B) Endoscopic view
demonstrating extension of the mass (black arrow) across the
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nasal septum to involve the left nasal cavity.
In addition to complete tumor resection, bilateral maxillary antrostomies and
sphenoethmoidectomies were performed as well as a posterior septectomy. The left middle
turbinate was also resected due to tumor involvement. There was no intraoperative
cerebrospinal (CSF) fluid leak.
The postoperative course was uneventful and a follow-up CT scan was obtained two weeks later
without evidence of residual disease, as seen in Figure 4.
FIGURE 4: Postoperative CT images. (A) Coronal and (B) axial
images showing complete tumor resection (arrows), bilateral
maxillary antrostomies and sphenoethmoidectomies and
posterior septectomy.
Review
CMF is a slow-growing and rare neoplasm consisting of chondroid, myxoid, and fibrous tissue.
CMF accounts for less than 0.5% of all bone tumors [2-4], with a slight male predominance [5].
Although it is most commonly found in the metaphysis of long bones, craniofacial involvement
has been reported and comprised 5.4% of the 278 CMF cases surveyed by Wu et al. [5]. This
benign, albeit locally aggressive tumor is most commonly found in patients in the second or
third decades of life [8]. The rare occurrence rate of CMF makes it a challenging disease to study
directly and the presentation of a single case is a relative limitation of the present study. An
examination of the literature reveals a number of studies with reported areas of involvement of
much of the skeleton. Within the head and neck, cases have been identified in the paranasal
sinuses, mastoid process, sella turcica, and clivus [9]. Additional details, including patient
demographic data, location, treatment, and follow-up of all reported cases of paranasal CMF
can be found in Table 1.
Author
Age
y,
mo,
or d/
Sex
Location Treatment Follow-up Clinicalpresentation
Duration
of
symptoms
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Keel et al.
[10]
65
y/F
Clivus with
extension to
sphenoid and
ethmoid sinuses
Curettage and radiation
Local
recurrence
after 6 mo;
after
radiation, 20
mo DF
2/3 patients in this
series presented with
headache while other
presented with nasal
obstruction
NA
Keel et al.
[10]
66
y/F
Clivus with
extension to
sphenoid and
ethmoid sinuses
Curettage 26 mo DF NA
Isenberg
et al. [6]
34
y/F Ethmoid sinus
Endoscopic excision,
ethmoidectomy 8 mo DF Difficulty breathing 3 y
Mendoza
et al. [11]
1
mo/M Ethmoid sinus Block resection 2 y DF Respiratory difficulty 1 mo
Nazeer et
al. [12]
20
d/M Ethmoid sinus Surgical resection 12 mo DF
Respiratory difficulty
since birth 20 d
Szmeja et
al. [13] 8 y/F Ethmoid sinus Total enucleation NA NA NA
Won et al.
[14] 
28
y/M Ethmoid sinus Partial curettage NA
Intermittent, pulsatile
pain of right temporal
area
Long-
standing
Cruz et al.
[15]
10
y/F
Ethmoid sinus
invading orbit
Coronal approach with
en bloc resection NA
Progressive
exophthalmos of left
eye
7 mo
Hashimoto
et al. [16]
32
y/M
Ethmoid sinus,
extending to frontal
sinus and orbit
Surgical resection 2 y DF
Painless left frontal
swelling and
progressive
exophthalmos
1 y
Azorin et
al. [17]
46
y/M Frontal sinus
Subfrontal approach,
superior orbitotomy, and
block resection, including
pericranium and
surrounding frontal bone
22 mo DF Right supraciliaryfrontal mass 18 mo
Wolf et al.
[18]
35
y/F
Frontal-sphenoid
junction with orbital
infiltration
Left craniotomy with
piecemeal removal NA Frontal headache 4 mo
Perez-
Fernandez
et al. [19]
60
y/M
Maxillary sinus with
extension into
ethmoid sinus
Endoscopic resection
and post-ethmoidectomy,
Caldwell-Luc
5 y DF
Left nasal obstruction
with recurrent
ipsilateral epistaxis
"several
months"
Koay et al.
[20]
57
y/F
Nasal bone with
extension to frontal
and ethmoid
sinuses
Incomplete surgical
excision NA
Slowly expanding,
painless swelling over
bridge of nose
2 y
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Baujat et
al. [21]
50
y/F
Nasal bone,
extension into
frontal and
ethmoidal sinuses
with dural
involvement
Frontal bone window with
dura removal 18 mo DF
Frontal headache,
pain, nasal
obstruction and
tearing
3 mo
Wang et
al. [9]
60
y/F Nasal septum
Complete surgical
removal 6 mo DF
No clinical discomfort
(MH: congenital right
aural atresia)
60 y
Veras et
al. [22]
60
y/F Nasal septum Surgical excision 12 mo DF
Incidental
(asymptomatic) NA
McClurg
et al. [23]
49
y/F
Nasal septum
extending into the
maxilla
Midface degloving with
resection of nasal
septum, left ethmoid, and
left partial maxilla
16 mo DF Sinonasal congestion 6 mo
Januszek
et al. [24]
51
y/F
Nasal septum,
extension into
maxillary and
sphenoid sinuses
Surgical resection
Recurrence
after 12 mo,
reoperated
NA NA
Frank et
al. [25]
26
y/M
Petrous/sphenoid
bones extending
into posterior
clinoid, sella, and
cavernous sinus
Complete surgical
removal NA Diplopia 1 mo
Vernon et
al. [26]
44
y/M Sphenoid sinus
Endoscopic sphenoid
sinusotomy and posterior
ethmoidectomy
NA Left retroorbital pain 3 mo
Morris et
al. [27]
52
y/F
Sphenoid sinus,
eroding floor of
sphenoid sinus
Endoscopic resection
with rim of normal bone 2 y DF
No sinonasal signs or
symptoms NA
Nazeer et
al. [12]
66
y/F
Sphenoid sinus,
extension into
nasopharynx and
sella
Surgical curettage
Local
recurrence
after 1 y,
curetted, 6
mo DF
Nasal obstruction Severalyears
TABLE 1: Treatment and outcome data for all reported cases of CMF in the paranasal
sinuses, arranged by location
Abbreviations: DF, disease-free; M, male; F, female; y, year; mo, month; d, day; NA, unable to obtain or not addressed in the article;
CMF, chondromyxoid fibroma
A review of the literature demonstrates inconsistent presenting symptoms. Table 1 suggests
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that clinical sequelae arise secondary to the mass effect rather than specific to the acute
pathology of CMF. The lack of specificity of symptoms highlights the importance of a thorough
examination and workup in obtaining an accurate diagnosis.
Given its rarity, an early differential would seldom, if ever, have CMF as the primary diagnosis.
More common lesions, such as a chordoma or chondrosarcoma, should be considered for any
lesion demonstrating calcification within a chondroid-like matrix [10]. These neoplasms
portend a worse prognosis than CMF, with 10-year survival rates of 50% for skull base
chondrosarcomas and 16-32% for skull base chordomas [28].
These lesions are also difficult to differentiate radiologically. The identification of calcifications
on CT should prompt the consideration of a cartilaginous or chondroid matrix-containing
lesion [23]. Although some CMF lesions contain foci of calcification, these are frequently
microscopic and, therefore, rarely visible on imaging [29]. Chondrosarcomas, by contrast,
contain prominent, easily seen calcifications [23]. Of the 191 cases of CMF that Wu et al.
studied, 87% had a purely lucent matrix while 15% had signs of mineralization [5]. MRI is the
preferred radiologic modality to understand the extent of the disease process, as it provides
information on soft tissue involvement. On MRI, these three lesions are all hypointense or
isointense on T1 and hyperintense on T2, with frequent enhancement via gadolinium contrast,
if used.
Given this overlap of imaging findings across various lesions, a detailed histopathologic
evaluation becomes crucial in making the proper diagnosis. In their series of 36 patients with
CMF, Zilmer and Dorfman reported a 22% initial misdiagnosis rate and pointed out the
potential of more aggressive treatment than is required, such as amputating the affected limb
for a benign lesion [30-31]. The World Health Organization defines CMF as “a benign tumor
characterized by lobules of spindle-shaped or stellate cells with abundant myxoid or chondroid
intercellular material separated by zones of more cellular tissue rich in spindle-shaped or
round cells with a varying number of multinucleated giant cells of different sizes’’ [32]. Stellate
or spindle-shaped cells have centrally located nuclei with finely dispersed or homogeneous
dark chromatin and eosinophilic cytoplasm. Nuclear pleomorphism and atypia are uncommon
in CMF and are more defining of chondrosarcoma [15,31,33]. Additionally, the intersecting
bands of myxochondroid tissue are not found in chondrosarcoma. According to Castle et al.,
diagnostic features of chondrosarcomas also include a “bubbly appearance to the stroma along
with degenerative and liquefactive changes” [31]. Chordomas, in contrast, have the
characteristic physaliferous cells (those with abundant, bubbly, or vacuolated eosinophilic
cytoplasm), which are nearly pathognomonic for the lesion [27].
Although the standard of treatment for CMF is surgical excision, the cosmetic and functional
consequences of extensive resection of craniofacial lesions have led many authors to
recommend curettage specifically for facial CMF with close follow-up. Baujat et al. asserted that
long-term control is best achieved via wide surgical resection by demonstrating the high
recurrence rate achieved after curettage [21]. Select cases, such as the one described above, may
be amenable to endoscopic resection.
Another reason to favor surgery involves the risk of residual tissue undergoing malignant
transformation. Although the transformation rate is low [34], cases of malignant
transformation have been reported, with an increased risk noted after radiation therapy
[4,30,35]. A location at or near the skull base, however, imposes additional difficulty in
obtaining complete resection [10]. As such, some authors have suggested postoperative
irradiation as an attempt to reduce recurrence [36].
Conclusions
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A review of the literature demonstrates that although an exceedingly rare tumor, representing
<0.5% of all bone tumors, CMF has been reported to occur in the sinonasal cavity. Although
CMF may appear similar to chondrosarcoma and chordoma on imaging, proper treatment
depends on histopathologic differentiation. A biopsy will reveal stellate cells within an
abundance of a myxoid or chondroid matrix. Although curettage may be necessary in the case
of inaccessible tumors, complete surgical resection is preferred to minimize the risk of
recurrence.
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